Surveillance of transmitted antiretroviral drug resistance among HIV-1 infected women attending antenatal clinics in Chitungwiza, Zimbabwe

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Tshabalala, Mqondisi ^a   Manasa, Justen ^a,c   Zijenah, Lynn S ^a   Rusakaniko, Simbarashe ^a   Kadzirange, Gerard ^a   Mucheche, Mary ^a   Kassaye, Seble ^b,d   Johnston, Elizabeth ^b   Katzenstein, David ^b  

^a UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDETIC ACID; NEVIRAPINE; PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ADULT; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; DISEASE TRANSMISSION; DRUG SURVEILLANCE PROGRAM; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRACTICE GUIDELINE; PREGNANT WOMAN; PRENATAL CARE; SCALE UP; SEROLOGY; SINGLE DRUG DOSE; VIRUS LOAD; ZIMBABWE; ANTIVIRAL RESISTANCE; HEALTH SURVEY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; VIROLOGY;

CALYPTE; HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; POPULATION SURVEILLANCE; VIRAL LOAD; ZIMBABWE;

EID: 79959241249     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021241     Document Type: Article

References (43)

1. DHHS (2008) Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents.
2. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304: 321-333.
3. Gazzard BG, Anderson J, Babiker A, Boffito M, Brook G, et al. (2008) British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 9: 563-608.
4. Euroguidelines (2001) Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance. AIDS 15: 309-320.
5. Condra JH, (1998) Resisting resistance: maximizing the durability of antiretroviral therapy [editorial; comment]. AnnInternMed 128: 951-954.
6. Blower S, Bodine E, Kahn J, McFarland W, (2005) The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. Aids 19: 1-14.
7. Velasco-Hernandez JX, Gershengorn HB, Blower SM, (2002) Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2: 487-493.
8. Kilby JM, Lee HY, Hazelwood JD, Bansal A, Bucy RP, et al. (2008) Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline. AIDS 22: 957-962.
9. Babic DZ, Zelnikar M, Seme K, Vandamme AM, Snoeck J, et al. (2006) Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naive patients in Slovenia, 2000-2004. Virus Res 118: 156-163.
10. Viani RM, Peralta L, Aldrovandi G, Kapogiannis BG, Mitchell R, et al. (2006) Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study. J Infect Dis 194: 1505-1509.
11. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, et al. (2002) Time trends in primary HIV-1 drug resistance among recently infected persons. Jama 288: 181-188.
12. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, et al. (2005) Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 192: 958-966.
13. Fox J, Dustan S, McClure M, Weber J, Fidler S, (2006) Transmitted drug-resistant HIV-1 in primary HIV-1 infection; incidence, evolution and impact on response to antiretroviral therapy. HIV Med 7: 477-483.
14. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, et al. (2002) Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347: 385-394.
15. Ross L, Lim ML, Liao Q, Wine B, Rodriguez AE, et al. (2007) Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIV-infected individuals from 40 United States cities. HIV Clin Trials 8: 1-8.
16. Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, et al. (2003) Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr 34: 281-288.
17. Zhou J, Phanupak P, Kiertiburanakul S, Ditangco R, Kamarulzaman A, et al. (2006) Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database. J Acquir Immune Defic Syndr 43: 501-503.
18. Bessong PO, Mphahlele J, Choge IA, Obi LC, Morris L, et al. (2006) Resistance mutational analysis of HIV type 1 subtype C among rural South African drug-naive patients prior to large-scale availability of antiretrovirals. AIDS Res Hum Retroviruses 22: 1306-1312.
19. Kassu A, Fujino M, Matsuda M, Nishizawa M, Ota F, et al. (2007) Molecular epidemiology of HIV type 1 in treatment-naive patients in north Ethiopia. AIDS Res Hum Retroviruses 23: 564-568.
20. Maphalala G, Okello V, Mndzebele S, Gwebu P, Mulima N, et al. (2008) Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006. Antivir Ther 13 (Suppl 2): 95-100.
21. Pillay V, Ledwaba J, Hunt G, Rakgotho M, Singh B, et al. (2008) Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 13 (Suppl 2): 101-107.
22. Kamoto K, Aberle-Grasse J, (2008) Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Ther 13 (Suppl 2): 83-87.
23. Abegaz WE, Grossman Z, Wolday D, Ram D, Kaplan J, et al. (2008) Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. Antivir Ther 13 (Suppl 2): 89-94.
24. Hamers RL, Siwale M, Wallis CL, Labib M, van Hasselt R, et al. (2010) HIV-1 Drug Resistance Mutations Are Present in Six Percent of Persons Initiating Antiretroviral Therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr.
25. Price MA, Wallis CL, Lakhi S, Karita E, Kamali A, et al. (2011) Transmitted HIV Type 1 Drug Resistance Among Individuals with Recent HIV Infection in East and Southern Africa. AIDS Res Hum Retroviruses 27: 5-12.
26. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks FC, (2008) Recommendation for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 13: 12.
27. (CDC) CfDCaP (2006) Interim reocmmendations for th use of the BED capture enzymeimmunoassay for incidence estimation and surveillance. Statement from the Surveillance and Survey and the Laboratory Working Groups to the Global AIDS Coordinator Atlanta CDC.
28. Parekh BS, Kennedy MS, Dobbs T, Pau C-P, Byers R, et al. (2002) Quantitative Detection of Increasing HIV Type 1 Antibodies after Seroconversion: A Simple Assay for Detecting Recent HIV Infection and Estimating Incidence. AIDS Research and Human Retroviruses 18: 295-307.
29. McDougal JS, Parekh BS, Peterson ML, Branson BM, Dobbs T, et al. (2006) Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimates by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses 22: 8.
30. Barnighausen T, Wallrauch C, Welte A, McWalter TA, Mbizana N, et al. (2008) HIV incidence in rural South Africa: comparison of estimates from longitudinal surveillance and cross-sectional cBED assay testing. PLoS ONE 3: e3640.
31. Hargrove JW, Humphrey JH, Mutasa K, Parekh BS, MacDougal JS, et al. (2008) Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay. AIDS 22: 8.
32. Laeyendecker O, Church JD, Oliver AE, Mwatha A, Owen SM, et al. (2010) Pregnancy does not affect HIV incidence test results obtained using the BED capture enzyme immunoassay or an antibody avidity assay. PLoS ONE 5: e13259.
33. Zijenah LS, Kadzirange G, Madzime S, Borok M, Mudiwa C, et al. (2006) Affordable flow cytometry for enumeration of absolute CD4+ T-lymphocytes to identify subtype C HIV-1 infected adults requiring antiretroviral therapy (ART) and monitoring response to ART in a resource-limited setting. J Transl Med 4: 33.
34. Manasa J, Musabaike H, Masimirembwa C, Burke E, Luthy R, et al. (2007) Evaluation of the Partec flow cytometer against the BD FACSCalibur system for monitoring immune responses of human immunodeficiency virus-infected patients in Zimbabwe. Clin Vaccine Immunol 14: 293-298.
35. Kassaye S, Johnston E, McColgan B, Kantor R, Zijenah L, et al. (2009) Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy. J Acquir Immune Defic Syndr 50: 9-18.
36. Guindon S, Gascuel O, (2003) A Simple, Fast, and Accurate Algorithm to Estimate Large Phylogenies by Maximum Likelihood Systems. Biology 52: 9.
37. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, et al. (2005) An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 21: 3797-3800.
38. Somi GR, Kibuka T, Diallo K, Tuhuma T, Bennett DE, et al. (2008) Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir Ther 13 (Suppl 2): 77-82.
39. Karita E, Price M, Hunter E, Chomba E, Allen S, et al. (2007) Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross sectional and longitudinal seroconverter specimens from Africa. AIDS 21: 6.
40. Bärnighausen T, Wallrauch C, Welte A, McWalter TA, Mbizana N, et al. (2008) HIV Incidence in Rural South Africa: Comparison of Estimates from Longitudinal Surveillance and Cross-Sectional cBED Assay Testing. PLoS ONE 3: e3640.
41. Mermin J, Musinguzi J, Opio A, Kirungi W, Ekwaru JP, et al. (2008) Risk Factors for Recent HIV Infection in Uganda. JAMA 300: 540-549.
42. Nesheim S, Parekh B, Sullivan K, Bulterys M, Dobbs T, et al. (2005) Temporal Trends in HIV Type 1 Incidence among Inner-City Childbearing Women in Atlanta: Use of the IgG-Capture BED-Enzyme Immunoassay. AIDS Research and Human Retroviruses 21: 537-544.
43. Hall HI, Song R, Rhodes P, Prejean J, An Q, et al. (2008) Estimation of HIV Incidence in the United States. JAMA 300: 520-529.